Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055638 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
A Phase 1 study, sponsored by Azevan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT02055638: Completed Phase 1 study, sponsored by Azevan Pharmaceuticals.
NCT02055638 is a Phase 1 study that has completed, run by Azevan Pharmaceuticals. The registered enrollment target is 97 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02055638, a Phase 1 study, has completed, sponsored by Azevan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED). Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will be randomized to either SRX246 or Placebo treatment groups. Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits throughout the trial. The study results will be determined based on any changes observed over the study period.
Interventions
- DRUG Placebo
- DRUG SRX246
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02055638
The ClinicalTrials.gov registry entry for NCT02055638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Azevan Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02055638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02055638 about?
NCT02055638 is a clinical study titled "Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder". This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED). Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a two-week baseline lead-in phase, study...
What is the current status of trial NCT02055638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2014-05. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02055638?
The interventions under investigation include: Placebo (DRUG), SRX246 (DRUG).
Who is sponsoring clinical trial NCT02055638?
This trial is sponsored by Azevan Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.